MiNK 10-Q: Going-Concern Warning, $7.5M Cash, First $0.2M Product Revenue
INKT sits 19% above its 52-week low of $8.48 on light trading volume (0.2× avg).
Summary
MiNK's Q3 10-Q carries a going-concern warning, with $7.5 million of cash against $5.1 million of nine-month operating burn, offset only by a first $0.2 million of named-patient product revenue.
Key Events · Earnings and Guidance · INKT
-
Going-Concern Warning Disclosed
The 10-Q states substantial doubt exists about MiNK's ability to continue as a going concern for one year after the filing date, absent additional funding.
-
Cash Down to $7.5 Million
Cash and cash equivalents fell to $7.5 million at September 30, 2026 from $13.4 million at December 31, 2025, while net cash used in operations rose to $5.1 million from $3.9 million a year earlier.
-
First Product Revenue: $0.2 Million
MiNK recognized its first pre-commercial product revenue, $0.2 million, from agenT-797 supplied on a paid, per-patient basis under the Brazil named-patient access program.
-
ATM Remains the Funding Lever
Under the B. Riley Sales Agreement, 313,478 shares were sold in the nine months for $4.4 million net proceeds, with no Q3 sales and roughly $30.6 million still available.
Analysis · INKT · Life Sciences
The Q3 numbers were already out on 2026-11-11, but the full 10-Q is where the going-concern language lands: management states substantial doubt exists about MiNK's ability to continue as a going concern for one year after filing. Cash fell to $7.5 million from $13.4 million at year-end 2025, and operating burn ran $5.1 million for the nine months versus $3.9 million a year earlier — roughly a year of runway only if the ATM keeps producing. Against that, the company booked its first $0.2 million of product revenue from agenT-797 in Brazil's named-patient program, a small but real commercial proof point. The $5.0 million Agenus note was repaid in January 2026, but $16.3 million is still owed to related parties. The funding gap is the story: expect further ATM sales or a partnership to bridge it.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INKT was trading at $10.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.4M. The 52-week trading range was $8.48 to $16.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.